Milestone Pharmaceuticals Q2 2024 Adj EPS $(0.14) Beats $(0.19) Estimate
Portfolio Pulse from Benzinga Newsdesk
Milestone Pharmaceuticals (NASDAQ:MIST) reported a Q2 2024 adjusted EPS of $(0.14), beating the analyst consensus estimate of $(0.19) by 26.32%.
August 08, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Milestone Pharmaceuticals reported a Q2 2024 adjusted EPS of $(0.14), which is better than the analyst consensus estimate of $(0.19). This positive earnings surprise could lead to a short-term increase in the stock price.
The better-than-expected EPS indicates that the company is performing better than analysts anticipated, which is generally a positive signal for investors. This could lead to increased investor confidence and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100